270 related articles for article (PubMed ID: 34046709)
1. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.
Daldrup-Link HE; Theruvath AJ; Rashidi A; Iv M; Majzner RG; Spunt SL; Goodman S; Moseley M
Pediatr Radiol; 2022 Feb; 52(2):354-366. PubMed ID: 34046709
[TBL] [Abstract][Full Text] [Related]
2. Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.
Adams LC; Jayapal P; Ramasamy SK; Morakote W; Yeom K; Baratto L; Daldrup-Link HE
AJR Am J Roentgenol; 2023 Apr; 220(4):590-603. PubMed ID: 36197052
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
[TBL] [Abstract][Full Text] [Related]
4. Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.
Theruvath AJ; Aghighi M; Iv M; Nejadnik H; Lavezo J; Pisani LJ; Daldrup-Link HE
Nanotheranostics; 2020; 4(4):195-200. PubMed ID: 32637297
[TBL] [Abstract][Full Text] [Related]
5. A comparison of ferumoxytol with gadolinium as contrast agents for the diagnostic magnetic resonance imaging of osteomyelitis.
Langsjoen J; Neuwelt A; Eberhardt S; Mlady G; Shukla U; Murali S; Pizanis C; Sillerud LO
Magn Reson Imaging; 2020 Sep; 71():45-54. PubMed ID: 32439428
[TBL] [Abstract][Full Text] [Related]
6. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans.
Muehe AM; Yerneni K; Theruvath AJ; Thakor AS; Pribnow A; Avedian R; Steffner R; Rosenberg J; Hawk KE; Daldrup-Link HE
Mol Imaging Biol; 2020 Jun; 22(3):722-729. PubMed ID: 31325083
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
[TBL] [Abstract][Full Text] [Related]
8. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
[TBL] [Abstract][Full Text] [Related]
9. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI.
Muehe AM; Siedek F; Theruvath AJ; Seekins J; Spunt SL; Pribnow A; Hazard FK; Liang T; Daldrup-Link H
Theranostics; 2020; 10(8):3612-3621. PubMed ID: 32206111
[TBL] [Abstract][Full Text] [Related]
11. Incidental ferumoxytol artifacts in clinical brain MR imaging.
Bowser BA; Campeau NG; Carr CM; Diehn FE; McDonald JS; Miller GM; Kaufmann TJ
Neuroradiology; 2016 Nov; 58(11):1087-1091. PubMed ID: 27704163
[TBL] [Abstract][Full Text] [Related]
12. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
Mukundan S; Steigner ML; Hsiao LL; Malek SK; Tullius SG; Chin MS; Siedlecki AM
Am J Kidney Dis; 2016 Jun; 67(6):984-8. PubMed ID: 26786296
[TBL] [Abstract][Full Text] [Related]
13. Ferumoxytol magnetic resonance imaging detects joint and pleural infiltration of bone sarcomas in pediatric and young adult patients.
Theruvath AJ; Rashidi A; Nyalakonda RR; Avedian RS; Steffner RJ; Spunt SL; Daldrup-Link HE
Pediatr Radiol; 2021 Dec; 51(13):2521-2529. PubMed ID: 34410452
[TBL] [Abstract][Full Text] [Related]
14. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
15. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study.
Iv M; Ng NN; Nair S; Zhang Y; Lavezo J; Cheshier SH; Holdsworth SJ; Moseley ME; Rosenberg J; Grant GA; Yeom KW
Radiology; 2020 Nov; 297(2):438-446. PubMed ID: 32930651
[TBL] [Abstract][Full Text] [Related]
16. Emerging applications for ferumoxytol as a contrast agent in MRI.
Bashir MR; Bhatti L; Marin D; Nelson RC
J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
[TBL] [Abstract][Full Text] [Related]
17. High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol.
Shahrouki P; Khan SN; Yoshida T; Iskander PJ; Ghahremani S; Finn JP
Pediatr Radiol; 2022 Mar; 52(3):501-512. PubMed ID: 34936018
[TBL] [Abstract][Full Text] [Related]
18. Impact of ferumoxytol vs gadolinium on 4D flow cardiovascular magnetic resonance measurements in small children with congenital heart disease.
Kollar SE; Udine ML; Mandell JG; Cross RR; Loke YH; Olivieri LJ
J Cardiovasc Magn Reson; 2022 Nov; 24(1):58. PubMed ID: 36352454
[TBL] [Abstract][Full Text] [Related]
19. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia.
Wise-Faberowski L; Velasquez N; Chan F; Vasanawala S; McElhinney DB; Ramamoorthy C
Cardiol Young; 2018 Jul; 28(7):916-921. PubMed ID: 29848399
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
